DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy

Xiaxia Man; Qi Li; Baogang Wang; He Zhang; Songling Zhang; Ziyi Li

doi:10.3389/fcell.2022.916725

DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy

Front Cell Dev Biol. 2022 May 10:10:916725. doi: 10.3389/fcell.2022.916725. eCollection 2022.

Authors

Xiaxia Man¹, Qi Li², Baogang Wang³, He Zhang¹, Songling Zhang¹, Ziyi Li²

Affiliations

¹ Department of Oncologic Gynecology, the First Hospital of Jilin University, Jilin, China.
² State and Local Joint Engineering Laboratory for Animal Models of Human Diseases, Academy of Translational Medicine, the First Hospital of Jilin University, Jilin, China.
³ Department of Cardiac Surgery, the First Hospital of Jilin University, Jilin, China.

Abstract

Breast cancer has become a leading cause of cancer-related deaths in women worldwide. DNA methylation has been revealed to play an enormously important role in the development and progression of breast cancer. DNA methylation is regulated by DNA methyltransferases (DNMTs), including DNMT1, DNMT2, and DNMT3. DNMT3 family has three members: DNMT3A, DNMT3B, and DNMT3L. The roles and functions of DNMT1 in breast cancer have been well reviewed. In this article, the roles of DNMT3A and DNMT3B in breast tumorigenesis and development are reviewed. We also discuss the SNP and mutations of DNMT3A and DNMT3B in breast cancer. In addition, we summarize how DNMT3A and DNMT3B are regulated by non-coding RNAs and signaling pathways in breast cancer, and targeting the expression levels of DNMT3A and DNMT3B may be a promising therapeutic approach for breast cancer. This review will provide reference for further studies on the biological functions and molecular mechanisms of DNMT3A and DNMT3B in breast cancer.

Keywords: DNMT3B; Dnmt3a; breast cancer; inhibitors; methylation.

Publication types

Review